Breaking News

Recipharm, Isofol in Modufolin Mfg. Pact

Recipharm Venture Fund invests $1.15 million in Isofol

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Recipharm and Isofol Medical AB have entered a collaboration for the development and manufacture of Isofol’s lead drug candidate Modufolin, an endogenous folate-based biomodulator currently being evaluated in two Phase I/II studies. Modufolin has the potential to increase the efficacy and decrease the side effects of chemotherapeutic agents used in the treatment of solid tumors.   Addionally, Recipharm Venture Fund has invested $1.15 million in Isofol Medical.    Carl-Johan Spak, executive vice ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters